P A
Bluelighter
- Joined
- Dec 7, 2008
- Messages
- 1,269
D2High occupancy isn't particularly relevant to healthy humans in vivo, as evidenced by the apparent lack of D2 agonist-associated [side]effects during the clinical trials. Rule of thumb: if none of the patients are vomiting, twitching, or hallucinating, it's probably not a functional D2 agonist, the hallucinations being particularly relevant in disorders like schizophrenia, which, interestingly enough, Provigil is being used to treat. And the facts that the molecule happens to both inhibit reuptake and weakly displace cocaine at the transporter don't predicate lumping modafinil's mechanism in with the rest of the classical pyshcostimulants as though the real-world clinical profile has lost relevance. None of the mechanisms described above do anything to explain modafinil's more selective behavioral properties and negligible incidence of side effects as compared to other contemporary catecholamine transporter blockers and substrates.
Directly increasing conductance across the membrane or amplifying presynaptic Na/Ca influx (by way of some of the mechanisms I mentioned in my other post) could theoretically allow for elevated displacement of transporter ligands and transient, voltage-dependent inhibition of monoamine reuptake (and stimulation of electrically evoked release) resembling that of the conventional stimulants, minus the stereotypy, euphoria, and locomotor effects. This theoretical RI/release mechanism would be similar to that of acetylcarnitine (which modestly releases dopamine and acetylcholine through selective nicotinic modulation/agonism) and hyperforin (broad-spectrum reuptake inhibition via presynaptic TRP6 activation on GABA, glutamate, 5-HT, DA, and NE neurons) on their target neurotransmitter systems. Regionally selective exocytosis of GABA neuron gap junctions would allow for enhanced H3 receptor binding alongside some of the low-level 'amphetamine-like' effects observed in higher doses.
On the other hand, modafinil could simply be exploiting an as-yet undiscovered chemical discrepancy, either by binding exclusively to an allosteric site on the transporter or acting on a regionally localized subunit. But I doubt it, if only because the "enhanced coupling" theory seems much more promising as a novel explanation for novel drug properties.
Directly increasing conductance across the membrane or amplifying presynaptic Na/Ca influx (by way of some of the mechanisms I mentioned in my other post) could theoretically allow for elevated displacement of transporter ligands and transient, voltage-dependent inhibition of monoamine reuptake (and stimulation of electrically evoked release) resembling that of the conventional stimulants, minus the stereotypy, euphoria, and locomotor effects. This theoretical RI/release mechanism would be similar to that of acetylcarnitine (which modestly releases dopamine and acetylcholine through selective nicotinic modulation/agonism) and hyperforin (broad-spectrum reuptake inhibition via presynaptic TRP6 activation on GABA, glutamate, 5-HT, DA, and NE neurons) on their target neurotransmitter systems. Regionally selective exocytosis of GABA neuron gap junctions would allow for enhanced H3 receptor binding alongside some of the low-level 'amphetamine-like' effects observed in higher doses.
On the other hand, modafinil could simply be exploiting an as-yet undiscovered chemical discrepancy, either by binding exclusively to an allosteric site on the transporter or acting on a regionally localized subunit. But I doubt it, if only because the "enhanced coupling" theory seems much more promising as a novel explanation for novel drug properties.